265,981 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. bought a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 265,981 shares of the company’s stock, valued at approximately $8,110,000.

Several other institutional investors have also recently made changes to their positions in the stock. Barclays PLC boosted its position in shares of Intellia Therapeutics by 15.0% in the third quarter. Barclays PLC now owns 256,626 shares of the company’s stock valued at $8,115,000 after acquiring an additional 33,558 shares during the period. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 14.7% in the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock valued at $347,966,000 after purchasing an additional 1,463,820 shares during the period. American Century Companies Inc. grew its position in shares of Intellia Therapeutics by 5.9% during the 3rd quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock valued at $8,449,000 after purchasing an additional 14,863 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Intellia Therapeutics by 13.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock worth $1,104,000 after purchasing an additional 4,255 shares during the period. Finally, Wellington Management Group LLP raised its position in shares of Intellia Therapeutics by 1.4% in the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after buying an additional 36,630 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the transaction, the executive vice president now owns 81,571 shares of the company’s stock, valued at $2,691,027.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.00% of the company’s stock.

Intellia Therapeutics Stock Up 1.4 %

Shares of NASDAQ:NTLA traded up $0.33 during midday trading on Friday, hitting $23.60. 1,294,988 shares of the stock traded hands, compared to its average volume of 1,217,743. The business’s 50 day moving average is $26.06 and its two-hundred day moving average is $27.30. The stock has a market capitalization of $2.28 billion, a PE ratio of -4.36 and a beta of 1.85. Intellia Therapeutics, Inc. has a one year low of $19.37 and a one year high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. The firm had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period last year, the company earned ($1.40) EPS. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.57 earnings per share for the current year.

Analyst Ratings Changes

NTLA has been the topic of a number of recent analyst reports. Wedbush reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. Canaccord Genuity Group increased their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Wolfe Research started coverage on Intellia Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $136.00 to $32.00 in a report on Friday, February 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $67.00.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.